SmartAnalyst, part of UDG Healthcare, has appointed Sasha Richardson as CEO.
With 24 years’ experience, most recently as a MD and senior leader in Ernst and Young’s Health Sciences & Wellness practice, Richardson is skilled in commercial strategy, innovation, value optimisation and transformation.
SmartAnalyst focuses on supporting bio-pharma innovation by driving the pipeline and portfolio value of pharmaceutical and biotech companies. Richardson succeeds founder and CEO Manu Bammi and VP of Research, Ritu Kishwar, to drive forward the business.
“SmartAnalyst thrives on evidence-driven innovation, curiosity and collaboration, and these are qualities that I strongly identify with,” said Richardson. “The pharmaceutical and biotech industry is constantly evolving and developing at a rapid pace. This past year alone has demonstrated the rate at which progress is happening in healthcare, and this extends beyond the current pandemic.
“Developments in oncology, for example, are transforming the management of cancers. New treatment options, combined with the rise of personalized healthcare, have the potential to change what a cancer diagnosis may mean. SmartAnalyst is well-placed to support these rapidly changing landscapes with our expertise and team of high performance-driven individuals; and this is a challenge I am ready for.”
SmartAnalyst provides strategy consulting services, HEOR / RWE solutions, and syndicated databases and insight reports. Focused on oncology, hematology, immunology & inflammation, neurosciences, cardiometabolic, ophthalmology and rare diseases, SmartAnalyst aims to improve patient outcomes and garner market success for client partners.
Part of the recently formed Advisory Ecosystem Model Ashfield Advisory, a business unit of Ashfield, SmartAnalyst works alongside Vynamic, Putnam Associates and STEM Healthcare, combining their expertise to provide integrated services to customers.
